Schedule 13D ownership disclosure

Atara Biotherapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 046513206

Event date: 2025-11-12

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Redmile Group, LLCReported CIK 0001425738

    Shares: 751,223.00 · Class: 9.9%

  • Jeremy C. GreenReported CIK 0001650527

    Shares: 751,223.00 · Class: 9.9%

  • RedCo I, L.P.Reported CIK 0001813157

    Shares: 347,442.00 · Class: 4.7%

  • Redmile Biopharma Investments II, L.P.Reported CIK 0001772230

    Shares: 452,153.00 · Class: 6.0%

  • Redmile Strategic Long Only Trading Sub, Ltd.Reported CIK 0002048243

    Shares: 376,377.00 · Class: 5.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-112574
Form type
SCHEDULE 13D/A
Filer
Atara Biotherapeutics, Inc.
CIK
CIK 1604464
Filed
Nov 14, 2025
Reporting period
Nov 12, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub